GPT and metabolic dysfunction-associated steatotic liver disease: A previous analysis of ALT in the clinical trial of treatment of nonalcoholic fatty liver disease in children (TONIC) showed that for every decrease of 10 U/L, the relative odds of histologic improvement and resolution of nonalcoholic steatohepatitis (NASH) were 1.31 and 1.26 respectively [13].